Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus CRL 1505
- Development stage
- Unknown
- Lead developer
- SACCO SYSTEM
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal
01
Overview
Lactobacillus rhamnosus CRL 1505 (also known as Lacticaseibacillus rhamnosus CRL 1505) is a specific probiotic bacterial strain originally isolated from goat milk. It is classified as a live biotherapeutic product (LBP) and is recognized for its potent immunomodulatory properties, particularly its ability to enhance respiratory mucosal immunity. The strain's mechanism involves a heat-stable peptidoglycan (PG05) that interacts with the innate immune system, modulating the activity of macrophages and dendritic cells to improve the clearance of respiratory pathogens. While it has been used in functional foods and dietary supplements to prevent infections, it is currently being evaluated in a clinical setting by the Royal Brisbane and Women's Hospital as a component of a multi-strain probiotic nasal rinse for patients with chronic rhinosinusitis (CRS) following nasal surgery.
- Other names
- Lacticaseibacillus rhamnosus CRL 1505L. rhamnosus CRL 1505
02
Targets
TLR2 (Toll-like Receptor 2)TLR3 (Toll-like receptor 3)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on lactobacillus rhamnosus CRL 1505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus CRL 1505.